评估子痫前期治疗性干预的随机对照试验结局报告情况
该系统评价检索至2016年1月的文献,纳入79项随机对照试验,涉及31615名产妇和28172名子代,评估55种干预措施。共报告119种不同结局,但临床重要结局报告不一致,子代结局尤其不足,作者建议未来试验采用核心结局集。
要点
- 79项随机对照试验报告119种结局,其中母体结局72种、子代结局47种。
- 母体死亡率仅11项试验(14%)报告,心血管疾病发病率仅16项试验(20%)报告。
- 子代神经发育结局仅6项试验(8%)报告,不足半数试验报告母婴伤害相关信息。
核心结论
- 大多数评估子痫前期干预措施的随机对照试验缺失临床重要结局信息,尤其忽视对子代有效性和安全性的评估。
- 作者认为未来子痫前期试验制定和实施核心结局集(最小数据集)可能有助于解决这些问题。
研究设计与样本
- 系统评价,检索 bibliographic 数据库自建库至2016年1月,纳入随机对照试验。
- 共纳入79项随机对照试验,报告31615名产妇和28172名子代的数据,评估55种不同干预措施。
主要发现
- 纳入试验共报告119种不同结局,包括72种母体结局和47种子代结局。
- 11项试验(14%)报告母体死亡,报告数据来自12422名参与者;16项试验(20%)报告心血管疾病发病率,报告数据来自14963名产妇。
- 43项试验(54%)报告胎儿结局,23项试验(29%)报告新生儿结局,28项试验(35%)报告子代死亡。
- 6项试验(8%)报告神经发育结局;不足半数纳入试验报告母体及其子代伤害相关的任何信息。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standardising outcome collection and reporting in pre-eclampsia trials requires an appraisal of current outcome reporting. OBJECTIVES: To map maternal and offspring outcome reporting across randomised trials evaluating therapeutic interventions for pre-eclampsia. SEARCH STRATEGY: Randomised trials were identified by searching bibliographical databases from inception to January 2016. SELECTION CRITERIA: Randomised controlled trials. DATA COLLECTION AND ANALYSIS: We systematically extracted and categorised outcome reporting. MAIN RESULTS: Seventy-nine randomised trials, reporting data from 31 615 maternal participants and 28 172 of their offspring, were included. Fifty-five different interventions were evaluated. Included trials reported 119 different outcomes, including 72 maternal outcomes and 47 offspring outcomes. Maternal outcomes were inconsistently reported across included trials; for example, 11 trials (14%) reported maternal mortality, reporting data from 12 422 participants, and 16 trials (20%) reported cardiovascular morbidity, reporting data from 14 963 maternal participants. Forty-three trials (54%) reported fetal outcomes and 23 trials (29%) reported neonatal outcomes. Twenty-eight trials (35%) reported offspring mortality. There was poor reporting of childhood outcomes: six trials (8%) reported neurodevelopmental outcomes. Less than half of included trials reported any relevant information regarding harms for maternal participants and their offspring. CONCLUSIONS: Most randomised trials evaluating interventions for pre-eclampsia are missing information on clinically important outcomes, and in particular have neglected to evaluate efficacy and safety in the offspring of participants. Developing and implementing a minimum data set, known as a core outcome set, in future pre-eclampsia trials could help to address these issues. TWEETABLE ABSTRACT: Future #preeclampsia research requires a core outcome set to reduce #research waste. @coreoutcomes @jamesmnduffy International Prospective Register of Systematic Reviews: CRD42015015529; www.crd.york.ac.uk/PROSPERO/display_record.aspID=CRD42015015529.
引用
- Duffy J, Hirsch M, Kawsar A, et al. Outcome reporting across randomised controlled trials evaluating therapeutic interventions for pre-eclampsia. BJOG. 2017. PMID: 28432737. doi:10.1111/1471-0528.14702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。